ストックスクリーナーアプリを入手
5.7873
8.99%
0.4773
前日終値:
$5.31
開ける：
$5.12
24時間の取引高:
4,247
Relative Volume:
0.38
時価総額：
$58.10M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-1.07%
1か月 パフォーマンス:
+7.37%
6か月 パフォーマンス:
-15.77%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$5.12
$5.80
1週間の範囲:
$5.12
$6.61
52週間の値動き範囲:
$3.81
$10.28
Serina Therapeutics Inc Stock (SER) Company Profile
SER を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SER
Serina Therapeutics Inc
|
5.7873 | 58.10M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Serina Therapeutics Inc (SER) 最新ニュース
Serina Therapeutics to Present at JonesResearch Virtual CNS Day - The Manila Times
Serina Therapeutics CEO to Showcase Revolutionary CNS Drug Technology: Key Presentation Details Revealed - Stock Titan
Serina Therapeutics Says May Offer And Sell Shares Of Common Stock Of Up To $13.3 Million - marketscreener.com
Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients - The Globe and Mail
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit - GlobeNewswire
Revolutionary Drug Delivery Tech Could Make mRNA Vaccines Safer: New Trial Data - Stock Titan
Serina Therapeutics closes $5 million funding for Parkinson’s trial By Investing.com - Investing.com Canada
Serina Therapeutics Secures $5 Million Funding - MarketScreener
Serina Therapeutics closes $5 million funding for Parkinson’s trial - Investing.com
Serina Therapeutics Secures $5 Million in Funding to - GlobeNewswire
Revolutionary Parkinson's Treatment Gets $5M Boost: Serina's New Drug Heads to Clinical Trials - Stock Titan
Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference - GlobeNewswire
Serina's Game-Changing POZ Platform Takes Center Stage at Major Healthcare Conference - Stock Titan
Serina Therapeutics Files For Mixed Shelf Of Upto $100 MillionSEC Filing - MarketScreener
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Serina Therapeutics to Present Novel Data on Non-Immunogenic Lipid Nanoparticles at ACS Spring 2025 Meeting - Nasdaq
Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting - GlobeNewswire
Serina Cuts $11.2M Debt, Secures $10M Investment While Revenue Drops 98% - Stock Titan
Jones Trading Initiates Coverage of Serina Therapeutics (SER) with Buy Recommendation - Nasdaq
Serina Therapeutics initiated with a Buy at JonesResearch - TipRanks
Serina Therapeutics Appoints Dr. Venkatesan to Board - TipRanks
Serina Therapeutics Appoints Dr. Jay Venkatesan to Board of Directors - Nasdaq
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors - GlobeNewswire
Former Alpine Immune Sciences Founder Who Led $4.9B Exit Takes Board Seat at Serina - StockTitan
Huntsville biotech firm partnering with Pfizer lands $10 million for Parkinson’s trial - MSN
Serina secures additional $5 million for Parkinson's trial - MSN
Serina secures additional $5 million for Parkinson's trial By Investing.com - Investing.com Australia
Stocks to Watch: Palantir Technologies, Synaptics, J&J Snack Foods, Serina Therapeutics - MarketWatch
Serina Therapeutics's Shares Up Following $5M of Equity Financing - MarketWatch
Serina Therapeutics Receives Second $5 Mln Tranche To Strengthen Cash Position - Marketscreener.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Serina Therapeutics receives funding to advance SER-252 into clinical trial - TipRanks
Serina Therapeutics Secures $5 Million for SER-252 Trials - TipRanks
Serina Therapeutics Receives Second $5 Million Tranche to - GlobeNewswire
Parkinson's Breakthrough: Serina Therapeutics Lands Premium-Priced $5M Investment to Advance Novel Treatment - StockTitan
Serina Therapeutics Secures Additional $5 Million Financing to Advance SER-252 into Phase 1 Trial for Advanced Parkinson's Disease - Nasdaq
Stocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics - MarketWatch
Serina Therapeutics Shares Rise After Sale of UniverXome Subsidiary - MarketWatch
Serina Therapeutics Sells UniverXome Subsidiary - MarketWatch
Serina Therapeutics Announces Sale of UniverXome Subsidiary - GlobeNewswire
Serina Therapeutics Achieves Debt-Free Status After $11.2M UniverXome Sale, Sharpens Focus on Parkinson's Drug - StockTitan
Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors - GlobeNewswire
Serina Therapeutics, Inc. Appoints Karen J. Wilson to its Board of Directors -January 14, 2025 at 05:25 pm EST - Marketscreener.com
Serina Therapeutics director Bailey Gregory buys shares worth $17,744 By Investing.com - Investing.com Australia
Serina Therapeutics director Bailey Gregory buys shares worth $17,744 - Investing.com
Serina Therapeutics expands equity incentive plan By Investing.com - Investing.com Australia
Serina Therapeutics expands equity incentive plan - Investing.com India
Serina Therapeutics to Present at Tribe Public’s Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024 - The Globe and Mail
Serina Therapeutics to Present at Tribe Public’s Webinar - GlobeNewswire
Serina Therapeutics to Unveil Breakthrough Parkinson's Treatment Strategy in Upcoming Webinar - StockTitan
Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit - GlobeNewswire
Serina Therapeutics Inc (SER) 財務データ
Serina Therapeutics Inc (SER) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Serina Therapeutics Inc (SER) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bailey Gregory | Director |
Dec 17 '24 |
Buy |
4.59 |
3,866 |
17,745 |
67,243 |
| Bailey Gregory | Director |
Sep 20 '24 |
Buy |
6.03 |
1,137 |
6,851 |
63,377 |
| Bailey Gregory | Director |
Sep 19 '24 |
Buy |
6.11 |
11,679 |
71,384 |
62,240 |
| Bailey Gregory | Director |
Sep 18 '24 |
Buy |
6.23 |
2,709 |
16,873 |
50,561 |
| MINTZ STEVEN | Director |
Sep 12 '24 |
Buy |
6.47 |
6,000 |
38,814 |
17,443 |
| Bailey Gregory | Director |
Aug 20 '24 |
Buy |
8.25 |
1,776 |
14,652 |
47,582 |
| Bailey Gregory | Director |
Aug 19 '24 |
Buy |
7.93 |
6,400 |
50,760 |
45,806 |
| Bailey Gregory | Director |
Aug 16 '24 |
Buy |
7.31 |
6,400 |
46,780 |
39,406 |
| Bailey Gregory | Director |
Aug 15 '24 |
Buy |
6.65 |
6,400 |
42,577 |
33,006 |
| MINTZ STEVEN | Director |
Aug 15 '24 |
Buy |
6.59 |
7,593 |
50,033 |
11,443 |
0.47%
2.63%
大文字化:
|
ボリューム (24 時間):